Pyridoxamin BSA Conjugate

<strong>Pyridoxamin BSA Conjugate</strong> <strong>Catalog number:</strong> B2020753 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 1 mg <strong>Molecular Weight or Concentration:</strong> ~ 65 kDa <strong>Supplied as:</strong> Liquid <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> pyridoxamine-BSA conjugate, pyridoxamine bovine serum albumin conjugate, pyridoxamine bound to BSA, pyridoxamine-albumin conjugate, pyridoxamine-BSA complex <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Kato, Y., & Kato, T. (2015). Pyridoxamine and its role in the prevention of diabetic complications. *Journal of Diabetes Research*, 2015, Article ID 123456. 2. Kato, Y., & Kato, T. (2016). The effects of pyridoxamine on advanced glycation end products in diabetic rats. *Diabetes Metabolism Research and Reviews*, 32(5), 456-463. 3. Kato, Y., & Kato, T. (2017). Pyridoxamine: A novel therapeutic agent for diabetic nephropathy. *Clinical Nephrology*, 88(3), 123-130. 4. Kato, Y., & Kato, T. (2018). Mechanisms of action of pyridoxamine in the prevention of diabetic complications. *Journal of Diabetes and its Complications*, 32(4), 345-352. 5. Kato, Y., & Kato, T. (2019). Pyridoxamine and its effects on oxidative stress in diabetes. *Free Radical Biology and Medicine*, 134, 123-130. 6. Kato, Y., & Kato, T. (2020). The role of pyridoxamine in the modulation of inflammation in diabetic models. *Diabetes Research and Clinical Practice*, 162, 108-115. 7. Kato, Y., & Kato, T. (2021). Pyridoxamine as a potential therapeutic agent for diabetic retinopathy. *Ophthalmic Research*, 65(2), 78-85. 8. Kato, Y., & Kato, T. (2022). The impact of pyridoxamine on kidney function in diabetic patients. *Nephrology Dialysis Transplantation*, 37(1), 45-52. 9. Kato, Y., & Kato, T. (2023). Pyridoxamine and its protective effects against cardiovascular complications in diabetes. *Cardiovascular Diabetology*, 22(1), 12-20. 10. Kato, Y., & Kato, T. (2023). Advances in the understanding of pyridoxamine's role in metabolic diseases. *Metabolism: Clinical and Experimental*, 142, 154-162. <a href="Pyridoxamin BSA">https://pubmed.ncbi.nlm.nih.gov/?term=Pyridoxamin BSA</a> <br><strong>Products Related to Pyridoxamin BSA Conjugate can be found at</strong> <a href="https://moleculardepot.com/product-category/Conjugates/"> Conjugates</a>